Engineered immune cells take on deadly brain tumors
NCT ID NCT05241392
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a therapy made from a patient's own immune cells, engineered to target a protein called B7-H3 found on glioblastoma cells. The cells are delivered directly into the brain via a small device. The study aims to find a safe dose and check for any signs that the treatment shrinks tumors or helps patients live longer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
B7-H3-targeting CAR-T cells
What this could lead to
If this works, it could point toward a new treatment option for recurrent glioblastoma, a brain cancer with few effective therapies.
What could go wrong
This is a very early, small Phase 1 trial focused on safety, so effectiveness is uncertain. Risks include serious side effects like cytokine release syndrome and neurotoxicity.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Tiantan Hospital
Beijing, Beijing Municipality, 100730, China